Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

Page Path

HOME
ARTICLE CATEGORY
Editorial

Editorial

Role of endoscopic treatment or balloon-occluded retrograde transvenous obliteration in patients with Child-Pugh class C end-stage liver cirrhosis and esophageal/gastric varices

Jin Wook Chung

Clin Mol Hepatol. 2019;25(2):181-182. Published online December 21, 2018

DOI: https://doi.org/10.3350/cmh.2018.1010

View: 5582 Download: 127 Web of Science: 2 Crossref: 2

Can hepatic steatosis really promote hepatitis B viral hepatocarcinogenesis? The jury is out on.

Won Kim

Clin Mol Hepatol. 2019;25(1):40-41. Published online December 28, 2018

DOI: https://doi.org/10.3350/cmh.2018.0101

View: 6768 Download: 104 Web of Science: 1 Crossref: 1

Biomarker microfibril-associated glycoprotein 4 for non-invasive diagnosis and therapeutic evaluation of hepatic fibrosis in patients with hepatitis C

Young Woo Eom, Soon Koo Baik

Clin Mol Hepatol. 2019;25(1):37-39. Published online December 11, 2018

DOI: https://doi.org/10.3350/cmh.2018.1011

View: 7239 Download: 101 Web of Science: 2 Crossref: 2

Cirrhotic cardiomyopathy: An independent prognostic factor for cirrhotic patients

Yun Bin Lee, Jeong-Hoon Lee

Clin Mol Hepatol. 2018;24(4):372-373. Published online December 11, 2018

DOI: https://doi.org/10.3350/cmh.2018.0098

View: 5018 Download: 106 Web of Science: 5 Crossref: 4

Rehabilitation for social reintegration in liver transplant patients

Jong Man Kim

Clin Mol Hepatol. 2018;24(4):370-371. Published online December 10, 2018

DOI: https://doi.org/10.3350/cmh.2018.1012

View: 4669 Download: 81 Web of Science: 2 Crossref: 1

Assessment of fibrotic burden among chronic hepatitis B virus-infected patients with normal transaminase level

Mi Young Jeon, Beom Kyung Kim, Seung Up Kim

Clin Mol Hepatol. 2018;24(4):367-369. Published online September 19, 2018

DOI: https://doi.org/10.3350/cmh.2018.1008

View: 6798 Download: 168 Web of Science: 4 Crossref: 4

Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?

Yong Kyun Cho

Clin Mol Hepatol. 2018;24(3):299-301. Published online September 7, 2018

DOI: https://doi.org/10.3350/cmh.2018.1006

View: 5834 Download: 106

Prognostic implications of trunk muscle mass in liver cirrhosis

Jimin Han, Won Kim

Clin Mol Hepatol. 2018;24(3):297-298. Published online September 10, 2018

DOI: https://doi.org/10.3350/cmh.2018.0069

View: 5269 Download: 111 Web of Science: 4 Crossref: 6

Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?

Jong Eun Yeon

Clin Mol Hepatol. 2018;24(3):294-296. Published online September 11, 2018

DOI: https://doi.org/10.3350/cmh.2018.1009

View: 6677 Download: 80 Web of Science: 2 Crossref: 2

Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion

Jin Wook Chung

Clin Mol Hepatol. 2018;24(2):135-136. Published online February 22, 2018

DOI: https://doi.org/10.3350/cmh.2018.1001

View: 7299 Download: 152

Clinical implication of hepatic volumetry for living donor liver transplantation

Woo Kyoung Jeong

Clin Mol Hepatol. 2018;24(1):51-53. Published online March 22, 2018

DOI: https://doi.org/10.3350/cmh.2018.1003

View: 6495 Download: 93 Web of Science: 1 Crossref: 1

Lamivudine: fading into the mists of time

Jonggi Choi, Young-Suk Lim

Clin Mol Hepatol. 2017;23(4):314-315. Published online November 28, 2017

DOI: https://doi.org/10.3350/cmh.2017.0110

View: 5742 Download: 124

Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?

Joon Yeul Nam, Jeong-Hoon Lee

Clin Mol Hepatol. 2017;23(4):311-313. Published online December 4, 2017

DOI: https://doi.org/10.3350/cmh.2017.0069

View: 6170 Download: 142

Use of sofosbuvir in chronic kidney disease: Is it necessary?

Tae Seop Lim, Sang Hoon Ahn

Clin Mol Hepatol. 2017;23(4):308-310. Published online September 26, 2017

DOI: https://doi.org/10.3350/cmh.2017.0109

View: 5944 Download: 118 Web of Science: 4 Crossref: 6

Surveillance of hepatocellular carcinoma: is only ultrasound enough?

Woo Kyoung Jeong

Clin Mol Hepatol. 2017;23(3):222-223. Published online September 19, 2017

DOI: https://doi.org/10.3350/cmh.2017.0046

View: 6675 Download: 163 Web of Science: 7 Crossref: 6

Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?

Yun Bin Lee, Jeong-Hoon Lee

Clin Mol Hepatol. 2017;23(3):219-221. Published online September 19, 2017

DOI: https://doi.org/10.3350/cmh.2017.0045

View: 7811 Download: 154 Web of Science: 1 Crossref: 2

Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?

Nae-Yun Heo

Clin Mol Hepatol. 2017;23(2):125-127. Published online June 23, 2017

DOI: https://doi.org/10.3350/cmh.2017.0106

View: 7254 Download: 141 Web of Science: 3 Crossref: 3

Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?

Do Young Kim

Clin Mol Hepatol. 2017;23(2):123-124. Published online June 23, 2017

DOI: https://doi.org/10.3350/cmh.2017.0107

View: 6964 Download: 119

Is scheduled second chemoembolization necessary for early stage hepatocellular carcinoma showing complete response after first chemoembolization?

Jin Wook Chung

Clin Mol Hepatol. 2017;23(1):31-33. Published online March 16, 2017

DOI: https://doi.org/10.3350/cmh.2017.0102

View: 6148 Download: 104 Web of Science: 1 Crossref: 1

Transient elastography can be integrated into routine clinical practice for the evaluation of portal hypertension?

Beom Kyung Kim

Clin Mol Hepatol. 2017;23(1):27-30. Published online March 24, 2017

DOI: https://doi.org/10.3350/cmh.2017.0101

View: 7103 Download: 114 Web of Science: 3 Crossref: 3

Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?

Byung-Cheol Song

Clin Mol Hepatol. 2016;22(4):439-442. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0108

View: 7664 Download: 111 Web of Science: 1 Crossref: 1

Does obesity increase the risk of hepatocellular carcinoma in chronic hepatitis B patients?

Byoung Kuk Jang

Clin Mol Hepatol. 2016;22(3):336-338. Published online September 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0104

View: 8134 Download: 117 Web of Science: 2 Crossref: 1

Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?

Hyung Joon Yim

Clin Mol Hepatol. 2016;22(2):238-240. Published online June 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0103

View: 8406 Download: 96 Web of Science: 1 Crossref: 1

What we know about paracentesis induced circulatory dysfunction?

Jeong Han Kim

Clin Mol Hepatol. 2015;21(4):349-351. Published online December 24, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.4.349

View: 9874 Download: 166 Web of Science: 3 Crossref: 4

P53 expression in hepatocellular carcinoma: influence on the radiotherapeutic response of the hepatocellular carcinoma

Yu Rim Lee, Soo Young Park

Clin Mol Hepatol. 2015;21(3):230-231. Published online September 30, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.3.230

View: 6525 Download: 70 Web of Science: 12 Crossref: 10

Hepatitis C virus infection in patients with hemophilia in Korea: Is antiviral therapy effective and safe?

Woo Sun Rou, Byung Seok Lee

Clin Mol Hepatol. 2015;21(2):122-124. Published online June 26, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.2.122

View: 8058 Download: 103 Web of Science: 2

Regression of liver cirrhosis: Orthodoxy or paradigm shift?

Su Jong Yu

Clin Mol Hepatol. 2015;21(1):22-23. Published online March 25, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.1.22

View: 6447 Download: 85 Web of Science: 2 Crossref: 1

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question

Hyun Woong Lee

Clin Mol Hepatol. 2014;20(4):345-346. Published online December 24, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.4.345

View: 5207 Download: 68 Web of Science: 1 Crossref: 1

Occult hepatitis B virus infection: clearance or disguise?

Jin-Wook Kim

Clin Mol Hepatol. 2014;20(3):249-250. Published online September 25, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.3.249

View: 7261 Download: 55

Are patients with alcohol-related fatty liver at increased risk of coronary heart disease?

Dong Hyun Sinn, Yong-Han Paik

Clin Mol Hepatol. 2014;20(2):151-153. Published online June 30, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.2.151

View: 5329 Download: 75

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Impact Factor

14.0
First decision

09 Days

Publication after acceptance

03 Days

*Last 12 months

MOST VIEWED MOST CITED

MOST VIEWED (Last 6 months)

Viewed By 5505	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5404	MAFLD: How is it different from NAFLD?
Viewed By 5214	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5094	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4725	Global incidence and prevalence of nonalcoholic fatty liver disease

MOST CITED (2022-2024)

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 90	MAFLD: How is it different from NAFLD?
Cited By 80	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051 FAX: +82-2-703-0071 E-mail: kasl@kams.or.kr

Copyright © The Korean Association for the Study of the Liver.

COUNTER

TODAY : 303

TOTAL : 1931406